University of Memphis

University of Memphis Digital Commons
Electronic Theses and Dissertations
7-19-2016

Characterization and Functional Evaluation of an Adhesive and
Injectable Chitosan Paste Blended with Polyethylene Glycol for
Bacterial Infection Prevention
Joel Martin Berretta

Follow this and additional works at: https://digitalcommons.memphis.edu/etd

Recommended Citation
Berretta, Joel Martin, "Characterization and Functional Evaluation of an Adhesive and Injectable Chitosan
Paste Blended with Polyethylene Glycol for Bacterial Infection Prevention" (2016). Electronic Theses and
Dissertations. 1444.
https://digitalcommons.memphis.edu/etd/1444

This Thesis is brought to you for free and open access by University of Memphis Digital Commons. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of University of
Memphis Digital Commons. For more information, please contact khggerty@memphis.edu.

CHARACTERIZATION AND FUNCTIONAL EVALUATION OF AN
ADHESIVE AND INJECTABLE CHITOSAN PASTE BLENDED WITH
POLYETHYLENE GLYCOL FOR BACTERIAL INFECTION PREVENTION

by
Joel Martin Berretta

A Thesis
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Master of Science

Major: Biomedical Engineering

The University of Memphis
August 2016

Copyright © 2016 Joel Martin Berretta
All rights reserved

ii

DEDICATION
I would like to dedicate this thesis to my family for their never-ending support
and encouragement, especially my parents.

iii

ACKNOWLEDGEMENTS
First I would like to thank my graduate advisor Dr. Haggard for his help and
guidance. Also, I would like to thank my committee members, Dr. Joel Bumgardner, Dr.
Amber Jennings, Dr. Harry Courtney, Dr. William Mihalko, and Dr. Betsy Tedder for
their help in my research and for Dr. Courtney’s assistance with the testing of antibiotic
activity against microorganisms.
The following individuals made valuable contributions to my study: Dr. Amber
Jennings for her help with cell culture processes, HPLC methods, animal studies, and her
statistical analysis knowledge. Drs. Mark Smeltzer and Karen Beenken for their help
with the infected mouse model at the University of Arkansas for Medical Sciences.
Cheyenne Rhodes for her help in the laboratory and further development of the chitosan
paste. Drs. Keaton Smith and Ashley Parker for their earlier paste and sponge studies.
Carlos Wells for his help with HPLC methods, statistical analysis programs, and
assistance during animal studies. Mike Harris and Chris Alexander for their help taking
time points during studies and with their help during animal studies and Diego Velasquez
Pulgarin for his guidance with cell culture. Research reported in this publication was
supported by the National Institute Of Arthritis And Musculoskeletal And Skin Diseases
of the National Institutes of Health under Award Number R01AR066050. The content is
solely the responsibility of the authors and does not necessarily represent the official
views of the National Institutes of Health.

iv

ABSTRACT
Surgeries to treat musculoskeletal wounds need to inhibit or prevent
contaminating bacteria from causing an infection for optimal wound healing. Current
local drug delivery biomaterial systems, such as bone cement beads and chitosan paste,
do not fully degrade and/or do not offer full wound coverage which may limit the
efficacy of antibiotic therapy, respectively. Chitosan paste is a biocompatible, degradable
local drug delivery system which allows for complete wound coverage and decreases the
diffusion distance of antibiotics to bacteria. This research used blended chitosanpolyethylene glycol (PEG) pastes to improve biocompatibility, increased degradation
rate, and provide efficient and effective elution of locally delivered antibiotics for
musculoskeletal wounds. PEG-blended chitosan pastes were tested against previously
studied acidic chitosan paste and neutral 1% chitosan sponge. The PEG-blended pastes
also were fabricated to have lower acidity compared to past formulations to improve
biocompatibility, maintain degradation properties, and to decrease the fabrication time.
The blended chitosan/PEG pastes were shown to be biocompatible and released active
antibiotics to prevent or eliminate infections in vivo.
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PREFACE
The main body of this thesis in Chapter 3 is a journal article entitled “Blended
Chitosan Paste for Infection Prevention: Preliminary Preclinical Evaluations.” This
manuscript will be submitted to the journal of Clinical Orthopaedics and Related
Research.
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CHAPTER 1
INTRODUCTION

Statement of Clinical Problem
A musculoskeletal wound occurs when bone and muscle tissue becomes damaged
to the point where the tissues are vulnerable to the environment [25]. Lacerations,
crushing forces, punctures, burns, and surgical incisions can all cause complex
musculoskeletal wounds [5]. Civilians have an estimated 20% chance of infection from
complex musculoskeletal wounds while soldiers have a 26.5% chance of infection, a
number that increases to 65% if their wound involves an open fracture [17, 41, 16, 51].
Complications arise when bacteria, such as Staphylococcus aureus (S. aureus) and
Pseudomonas aeruginosa (P. aeruginosa), contaminate these wounds. These pathogenic
microorganisms form biofilms and cause decreased susceptibility and increased
resistance to certain antibiotics through the exchange of genes [16, 13, 7] and this
resistance can also be transferred between bacteria [2, 21]. Increasing the antibiotic
levels to address increased resistance can cause harmful systemic side effects [20, 15].
Many biomaterials, such as polylactic acid and polyglycolic acid, currently being
used for local drug delivery devices, but many of these devices still leave behind nonbiocompatible byproducts that are from rapid degradation, partial degradation, or even no
degradation [15, 40]. Additional surgeries or procedures are required to remove these
devices when no degradation or incomplete degradation occurs or to address nonbiocompatible reactions to the device degradation products [40, 8]. Another common
problem with these delivery devices is that they do not offer complete wound coverage.
Developing a local drug delivery system that does not require additional surgeries for
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removal, broadens wound coverage, offers an expanded antibiotic selection, and causes
less wound drainage would make for an ideal delivery system to prevent infection.
Hypothesis and Research Objectives
Chitosan paste blended with polyethylene glycol (PEG) will form a biocompatible
and biodegradable local delivery system that is used for point-of-care loading of various
antibiotics to prevent bacterial infections in musculoskeletal injuries. Past research on
chitosan paste required extensive modification of the ratio of acidic and neutral sponges
to improve cell/tissue compatibility and lessen composite acidity. The hypothesis is that
lowering the acidity of the chitosan pastes will improve the compatibility while
maintaining functionality of the previous composite pastes and eliminate the use of
mixing neutral and acidic sponges while maintaining effective local antibiotic delivery
function. Research goals are:


To determine a paste combination made from chitosan and PEG that is
injectable from a modified syringe while exhibiting improved
cytocompatibilty compared to neutral 1% chitosan sponges



To find an enhanced formulation that offers complete wound coverage and is
able to elute active antibiotics to prevent infections

Through in vitro evaluations such as elution and cytocompatibility, the most effective
combinations will be determined and evaluated in functional in vivo studies. This
hypothesis can be broken down into two major aims:
 Aim 1: Refine range of paste variations using chitosan and PEG. Test and screen
pastes for degradation, elution, activity, injectability, adhesion, and
cytocompatibility.
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 Aim 2: Test selected paste variations in proof of principle in vivo studies for
biocompatibility and infection prevention
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CHAPTER 2
LITERATURE REVIEW

Musculoskeletal Wounds
Musculoskeletal wounds occur when muscle and bone tissue becomes damaged,
limiting their natural functions in movement and support, among others [25]. These
injuries can be brought on by lacerations, crushing forces, punctures, burns, and surgical
incisions [5]. An estimated ten percent of American civilians will experience a
musculoskeletal wound and require hospitalization [5]. From Operation Enduring
Freedom and Operation Iraqi Freedom alone, American soldiers have experienced over
50,000 musculoskeletal injuries [33]. Musculoskeletal injuries are one of the most
prevalent forms of injuries, accounting for more than three out of five accidental injuries
per year and one of the leading causes of death in all age groups [5]. In both the civilian
and military sectors, billions of dollars are spent treating and researching musculoskeletal
wounds and injuries. The average cost per patient hospitalized for a musculoskeletal
wound was $25,000 in 2004 [17, 33].
Wound Management
Rapid treatment of musculoskeletal injury is a crucial element in reducing the
risks of malunions, nonunions, infection, and amputation while also increasing the
recovery time and quality of life for the patient [34]. Emergency first aid, fixation,
irrigation, dressings, and closures are common methods used in the treatment of complex
musculoskeletal wounds [34]. Systemic antibiotic therapy, debridement, and irrigation
are administered in most musculoskeletal wounds first in the emergency room (ER) in
order to reduce the amount of contamination and pathogens in the wound bed [11]. The
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musculoskeletal injury is fixed internally or externally and closed to keep out any
additional contaminants [11]. Surgeons then evaluate the simple or complex fractures
and decide between a rapid treatment or a definitive treatment to achieve the greatest
bone repair. Before the final wound dressing is applied, moist dressings may be packed
into the wound, which will promote angiogenesis, before the wound has been closed [34].
Along with these moist dressings, antibiotics can be used to help treat the wound.
Antibiotics, that are typically delivered systemically through oral administration or
intravenous injection, are used to fight infection but may be ineffective if the vasculature
around the musculoskeletal injury is damaged [41, 20].
Wound Complications
When the vasculature surrounding the injury site becomes damaged, this
vasculature loss often leads to decreased numbers of immune cells that are able to reach
the wound, which in turn inhibits the ability of the immune system to inhibit infection
and also decreases the amount of systemically administered antibiotic that can reach
wounded tissue [41, 20]. Due to low antibiotic levels and limited number of immune
cells, bacteria numbers can increase rapidly and can spread leading to infection in the
musculoskeletal injury. Complex civilian musculoskeletal wounds have an estimated
20% chance of infection while injured soldiers have a 26.5% chance of their
musculoskeletal wounds becoming infected and the incidence of infection increases to
65% if soldiers experience an open fracture [13, 41, 16, 51]. Soldiers are often exposed
to bombs, explosives, or gunshots which can result in open fractures that can be highly
susceptible to infection in the damaged tissue and bone [30]. Infections in
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musculoskeletal wounds are difficult to treat and severely hinder healing often leading to
additional surgeries, costs, and treatment time [3].
Wound Infection Complications
To prevent bacterial infections in a musculoskeletal wound, the bacteria in the
wound needs to be identified and eliminated. Bacteria, such as Staphylococcus aureus (S.
aureus) and Pseudomonas aeruginosa (P. aeruginosa), can form biofilms (when bacteria
attach to a surface) which decreases their susceptibility to certain antibiotics [16, 13, 7]
and this resistance can be transferred between bacteria [2, 21]. Also S. aureus and P.
aeruginosa are common pathogenic microorganisms in many musculoskeletal wounds
and infections [16]. As the use of antibiotics increases, bacteria have gained a tolerance
to many commonly used antibiotic drugs [2, 21]. Bacterial resistance used to be
primarily found in hospitalized patients because the bacteria that were found in the
hospital gained tolerance against antibiotics being used to treat patients. Now, antibiotic
resistant bacteria can be found in community-acquired infections as well [2, 21].
Bacterial interactions, adaptations, and metabolic activity, especially in a biofilm, have
brought about the need for advanced therapies, including increased concentration of local
antibiotics to treat these infections [15, 10]. High levels of systemic antibiotics can cause
harmful side effects, such as nausea and hypersensitivity, to other organs and tissues in
the human body [20, 15]. As an alternative to high systemic antibiotics, local antibiotic
delivery system can be applied to increase the local antibiotic levels to inhibit the
infection in the wound without subjecting the patient to elevated systemic antibiotic
levels [20, 15].
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Current Local Drug Delivery Devices
Though there are many types of biomaterials currently being used as local drug
delivery devices, many of these biomaterials still leave behind potentially nonbiocompatible byproducts due to rapid degradation. Degradable biomaterials such as
polylactic acid (PLA) and polyglycolic acid (PGA) are used for local delivery, however,
they can have non-biocompatible degradation byproducts [15]. These remaining
degradation products may not be tissue compatible. When incomplete degradation or no
degradation occurs, additional surgery is required to remove the remaining pieces of the
material [8]. Polymethylmethacrylate (PMMA) is a non-degradable bone cement that is
commonly used to locally deliver antibiotics for musculoskeletal wounds [1]. When
mixed with antibiotics, PMMA has been shown to reduce infections and acts as a
structure to stabilize fractures or large bone defects [1]. However, PMMA has decreased
material strength when it is loaded with antibiotics [1]. Due to PMMA not being
biodegradable, an additional surgery is required to remove the PMMA for complete bone
and wound healing to occur. Another short-coming of the use of PMMA for local
antibiotic delivery is that after the antibiotics have been depleted, bacteria could begin to
adhere to the implant and become a site for infection [1].
Hydrogels are also used for local drug delivery. These hydrogels can be used to
release antibiotics and have desirable properties such as being formable during surgery
and being adhesive to wound tissue [22]. These hydrogels can be administered through a
needle which increases their use flexibility but using these gels for larger wounds with a
small needle may become time consuming in surgery and may not provide full wound
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coverage. Another commonly used drug delivery device is the bio-ceramic calcium
sulfate, which acts as a local drug delivery system and a scaffold for bone repair [1, 48,
47]. Calcium sulfate is completely biodegradable and promotes bone growth, but, much
like PMMA, has disadvantages. Having a high resorption rate, calcium sulfate can leave
partial formation of regenerated tissue. Also calcium sulfate can exhibit a fast release of
antibiotics leading to decreased antibiotic levels in late elution time points to inhibit
infections [40, 1, 18]. Because of the high resorption rate, the calcium sulfate can cause
sterile drainage in the wound [40]. Having a local drug delivery system that does not
require additional surgeries for removal, has enhanced wound coverage, expanded
antibiotic selection, and less wound drainage is an ideal delivery system. Developing a
local drug delivery system made from chitosan could potentially solve some of these
issues. Chitosan has properties of tissue compatibility, complete degradation to
biocompatible byproducts, and can be loaded with multiple antibiotics [12].
Chitosan
Chitosan is a linear amino polysaccharide that is a product of the process of
alkaline deacetylation of chitin from the exoskeletons of insects and crustaceans.
Chitosan, which can be made from chitin, can be obtained inexpensively and in large
quantities from the fishing industries that would otherwise be thrown out as waste [1].
Chitosan and chitin have been studied and proven to have many biomedical uses
including drug delivery, bone healing properties, and wound healing [1, 12]. Chitosan is
a non-toxic material that has high biocompatibility [12]. Along with being
biocompatible, chitosan is also biodegradable [12]. Chitosan is distinguished from chitin
by its degree of deacetylation (DDA). Chitosan has more than 50% of its acetyl
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functional groups removed while chitin has less than 50%. Studies have shown that
chitosan used to treat musculoskeletal wounds degrade at different rates while chitosan
degraded nominally [44, 28, 31]. Chitosan has been investigated for local drug delivery
because of its biocompatibility properties and that its polymeric cationic characteristics as
well as reactive functional groups that allow for many customizations and alterations to
specialize the chitosan’s use [1, 12]. Being able to include different compounds and
reactants within chitosan drug delivery system broadens the applications for the use of
chitosan sponges to treat multiple ailments [36]. In humans, chitosan is degraded
chemically through acid catalyzed degradation or through the use of enzymes by the
process of depolymerization [12]. Enzymatic degradation is performed by lysozyme in
the body, which has also been shown to degrade chitosan in vitro. Lysozyme hydrolyzes
chitosan’s glycosidic bonds into glucosamine and saccharide degradation byproducts [48,
9]. These byproducts, which are polysaccharides, are compatible and are absorbed
gradually back into the body [48, 9].
Chitosan as a Local Drug Delivery Device
Multiple types of chitosan devices have been designed for medical applications
including membranes and scaffolds which assist in bone regeneration, beads that are
preloaded with growth factors and antibiotics, films and coatings to apply on implants,
pastes for use of delivery drugs, and sponges used for wound dressings [4, 43, 26, 38, 32,
37]. Sponges can be made with different thicknesses and pore sizes to allow for different
amounts of absorption capacity while also allowing the wound to exchange fluids with
the sponge and protecting the wound from outside bacteria [37]. In the case of chitosan
sponges, lyophilization is used to make the sponge more porous which, in combination
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with greater surface area, allows for loading high concentrations of aqueous antibiotic
solutions [38]. This increased porosity enhances the sponge’s ability to be used as a drug
delivery device and as a scaffold to be used for wound and bone healing. Chitosan
sponges, when made, are acidic and require neutralization through the rinsing of
deionized water in order for the pH levels to become neutral to help promote
biocompatibility.
Chitosan Sponges with Polyethylene Glycol
Chitosan sponges were developed to be used as an adaptable drug delivery system
that is biocompatible, degradable, and to be loaded with antibiotics [18, 43]. These
sponges have been further modified at the University of Memphis with the addition of
polyethylene glycol (PEG) which is a water soluble polymer that enables the sponge to be
loaded with hydrophobic dispersants and antifungals [36, 37]. PEG has low toxicity and
helps to increase the biocompatibility, elution, and degradability over the neutral chitosan
sponges.
Decreasing Diffusion Distance
While chitosan sponges and PMMA beads are extremely useful for antibiotic
delivery, they often are limited in their ability to conform to all the small crevices in a
complex wound site which can allow the antibiotic to become diluted. Chitosan paste
may solve this clinical issue as shown in Figure A by being able to seep into the wound
bed and combat the bacteria found in the wound. Sponges loaded with PEG will be able
to degrade at a quicker rate which allows the sponge to break down, release antibiotics,
and combat the bacteria found in a wound.
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Figure A: Illustration of antibiotic diffusion distances between different biomaterials
Chitosan Paste
Chitosan paste was developed to have the properties of the neutral chitosan
sponges, like biodegradability and biocompatibility, while also having the additional
property of injectability. The composite combines the solid elements of chitosan sponge
with a paste-like gel carrier for a greater ability to deliver antibiotics to the infected area
[19]. The chitosan paste also improves on chitosan’s adhesiveness which helps maintain
the device within the wounded area allowing for higher drug diffusion between the
device and the damaged tissue with contaminating microorganisms. Being moldable, the
paste is able to fit in tight crevices and offer full wound coverage. From Figure A, more
wound coverage and a decrease in diffusion distance, the paste is better equipped to
penetrate deeper into infected areas and tissues which will enhance the effectiveness of
the antibiotic therapy through a decreased diffusion distance. The biopolymer chitosan
paste can be altered to control elution and degradation rates for more consistent results.
The paste is activated by a clinician on site with water-soluble antibiotics which enables
the clinician to customize a device specific for the patient’s needs based on the doctor’s
evalutions [19]. Preliminary, in vitro, and in vivo studies to date have shown that
11

additional research is needed to further the functionality of the chitosan paste. These past
chitosan paste studies have shown that the degradation rates can be variable and could
potentially produce a moderate inflammatory response in animal models from an
injectable chitosan drug delivery system. Smith et al. has also showed from these
evaluations that the paste is easily adhesive, degradable and active in preventing bacterial
infections but were too acidic [39, 42]. A continuation of the chitosan paste research was
to use different formulations of acidic and neutral chitosan sponge to make chitosan
paste. Rhodes et al. tested different ratios (60:40, 40:60, and 50:50) and found that the
50:50 acidic to neutral sponge offered improved biocompatibility, degradation, and
elution.
Current Work: Chitosan Paste Blended with Polyethylene Glycol and Lowered
Acidity
For the paste device investigated in this body of work, two new paste
formulations were created with the aim of lowering the acidity of the acidic sponge and
alleviating the need for using a neutral/acidic sponge combination to fabricate chitosan
paste. In the making of the chitosan sponges, acetic acid is used to dissolve the chitosan
into the solution. While the acetic acid is used for dissolving chitosan, the acid also
makes the sponges used for the paste too acidic for ideal cytocompatibility. The first type
of paste had the acetic acid was lowered from 1% to 0.85% and then was blended with
1% of 8,000 g/mol PEG and 1% chitosan. The second formulation also had the acetic
acid lowered to 0.85% but was made with 0.5% of 8,000 g/mol PEG and 1% chitosan.
Rhodes et al. 50:50 combination paste will be used as a control to compare results for
these two new paste formulations. These three types of paste will be tested for
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cytocompatability, degradability, injectability, adhesivity, and antibiotic elution. The
pastes will be tested in vivo in a rat tibia model to assess the biocompatibility of the
pastes with both hard and soft tissue. The evaluation of the pastes will be assessed
histologically to determine how the cells interact with each formulation. The paste’s
ability to prevent infection with biofilm bacteria will be evaluated in an infected mouse
pin model. A summary of past researchers and their improvements to the development of
chitosan sponge and paste can be found in Table A.
Table A: Summary of past research for chitosan sponge and paste. (Gamma and EtO refer
to gamma sterilization and ethylene oxide sterilization)
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CHAPTER 3
BLENDED CHITOSAN PASTE FOR INFECTION PREVENTION:
PRELIMINARY AND PRECLINICAL EVALUATIONS

Abstract
Local drug delivery devices offer an improved method for delivering antibiotics
for musculoskeletal wounds. However, current devices do not allow for complete wound
coverage and do not address the need for reducing the antibiotic diffusion distance to help
prevent contamination by bacteria or other microorganisms. We blended
chitosan/polyethylene glycol (PEG) pastes to increase biocompatibility, decrease
fabrication time, and to lower the diffusion distance of the antibiotics. Along with using
a lowered acid concentration, the blended paste formulations were fabricated with
differing amount of chitosan and PEG composites. Are the blended pastes biocompatible
and biodegradable? Will they elute active antibiotics to inhibit bacteria in vitro? And are
they able to prevent infection in a preclinical model with hardware? Our blended paste
formulations were tested in vitro for elution, activity, cytocompatibility, degradability,
and injectability along with in vivo models for biocompatibility and infection prevention.
The blended pastes were shown to elute active antibiotics above the minimum inhibitory
concentration in vitro and in vivo as well as having comparable biocompatibility than the
neutral 1% chitosan sponges. Our blended chitosan/PEG composite pastes exhibited
quicker degradation rates than the chitosan sponge along with comparable
cytocompatibility/biocompatibility and infection prevention. Blended chitosan/PEG
pastes can be used to deliver active antibiotics to musculoskeletal wounds to prevent
infection and to provide a greater wound coverage.
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Introduction
Musculoskeletal wounds account for over 60% of accidental injuries in the United
States [5]. A musculoskeletal injury can affect both civilians and military populations
with around 10% of American civilians experiencing a musculoskeletal wound [5].
Administering treatment to an injury quickly is crucial in decreasing risks of infection,
malunions, nonunions, and amputation while improving the recovery time and quality of
life for the patient [34]. When the vasculature surrounding the injury site becomes
damaged, a decrease in immune cells that are able to reach the damaged tissue occurs
which results in a decrease in the systemic antibiotic therapy’s effectiveness against
contaminating bacteria in the wound [41, 20]. Complex civilian musculoskeletal wounds
have an estimated 20% chance of infection while there is a 26.5% chance of a soldier’s
wounds becoming infected and up to 65% if their wounds involve an open fracture [17,
41, 16, 51]. Bacteria, such as Staphylococcus aureus (S. aureus) and Pseudomonas
aeruginosa (P. aeruginosa), are common pathogens in musculoskeletal wounds and can
form biofilms and gain resistance to certain antibiotic concentrations [16, 13, 7, 2]. This
resistance can also be transferred between bacteria [21]. To address contaminated injury
sites, a local antibiotic delivery system may be utilized to increase the antibiotic levels in
the wound to prevent infection without risking patient side effects from high systemic
antibiotic levels [20, 15].
Many types of biomaterials, such as bone cement beads and calcium sulfate, are
being used as local drug delivery devices. These devices can leave behind nonbiocompatible degradation products due to rapid, partial, or no degradation and can cause
sterile drainage in the wound [15, 40, 1]. Developing a local drug delivery system that
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could potentially have more compatible degradation byproducts, requires no additional
surgeries, and decreases the diffusion distance would be helpful in treating
musculoskeletal injuries.
In previous studies, chitosan/PEG sponges were developed to be used as an
adaptable drug delivery system that is biocompatible, degradable, and can be loaded with
antibiotics. But they were not able to offer full wound coverage for enhanced infection
prevention and treatment [18, 43]. Our laboratory has fabricated a chitosan paste blended
with PEG to improve the paste’s biocompatibility, biodegradability, antibiotic delivery
properties, provide a greater wound coverage, and decrease diffusion distance as shown
in Figure 1.

Figure 1: Illustration of antibiotic diffusion distances between different biomaterials
Chitosan is a linear amino polysaccharide that is a product of the process of
alkaline deacetylation of chitin from the exoskeletons of crustaceans [1]. Chitosan is
biocompatible, biodegradable, adhesive, and has reactive side groups [5, 1]. Chitosan
sponges have been blended with PEG in previous research to aid in degradation and
biocompatibility [36]. The PEG has known biocompatibility, is used in pharmaceuticals,
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and helps to increase the biocompatibility and degradability over the initial neutral
chitosan sponges [36].
Our goal is to develop a biocompatible local drug delivery device that is able to
elute active antibiotics in vivo. To determine how effective these paste formulations are,
we need to answer some questions. Are the blended pastes injectable from a modified
syringe? Will they adhere to the wound site and not migrate? Are they biocompatible
and biodegradable? Will they elute active antibiotics to inhibit bacteria in vitro? And are
they able to prevent infection in a preclinical model with hardware?
Materials and Methods
Fabrication
The chitosan/PEG paste was fabricated using Chitopharm S chitosan powder
(Chitinor AS, Tromsø, Norway) with an 82.46 ± 1.679 degree of deacetylation and an
average molecular weight of 250.6 kDA. The 1%:1% paste {D} formulation was made
by dissolving 1% w/v of 8,000 g/mol PEG into a 0.85% v/v of acetic acid in ultrapure
water solution and then dissolving 1% w/v of chitosan. The solution is then frozen
overnight, lyophilized, and ground up. The process to manufacture the 1%:0.5% paste
{C} is the same with the exception of the amount of PEG being 0.5% w/v of 8,000 PEG.
For the neutral portion of the paste {B}, 0.5% w/v of 6,000 g/mol PEG (Sigma Aldrich,
St. Louis, MO) was dissolved in a 1% v/v acetic acid in deionized water solution and,
following dissolution, 0.5% w/v of chitosan was dissolved in the same solution. The
acidic portion of the paste {A} was made in the same manner, but dissolving only 1 % of
chitosan alone in the acetic acid solution. Both solutions for the neutral and acidic
sponges were cast into 500 mL containers at a volume of approximately 333 mL, frozen
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overnight at -20 °C, and lyophilized in a benchtop freeze dryer (LabConco, Kansas City,
MO) to create acidic, dehydrated sponges. To obtain the neutral sponges, they were
immersed in 0.25 M sodium hydroxide (NaOH) and washed with deionized water until a
neutral pH was reached, frozen at -20 °C overnight, and lyophilized again to create the
neutral, dehydrated sponges. Both the acidic and neutral sponges were ground separately
into small flakes (≤ .3 cm) and then combined in a 1:1 weight ratio to be used to make the
50:50 paste (Table 1).
Table 1: Compositions of the sponges used to make the 50:50 (Type A & B), 1%:0.5%
(Type C), and 1%:1% (Type D) pastes

The flakes are hydrated with a phosphate buffered solution (PBS) in deionized water at
7.5 times the dehydrated weight of solid flakes. All samples used for biological testing
were sterilized with ethylene oxide gas (EtO) prior to hydration and allowed to degas for
a minimum of 24-48 hours. The steps used for preparation of the chitosan paste for
sterilization are illustrated in Figure 2.
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Figure 2: Steps for how chitosan paste was prepared for EtO sterilization prior to being
hydrated
Elution
Elution studies were conducted with a combination of vancomycin and amikacin
antibiotics loaded in a 10 mg/mL concentration. The pastes and neutral 1% control
sponge were aliquoted into tubes at approximately 0.8 grams and were then hydrated with
6 mL (7.5 x the dehydrated paste weight) of the antibiotic solution (n = 3). They were
then placed into a metal, hemispherical container with numerous holes (approximately
1.5 mm in diameter) and the opening was wrapped with parafilm while covering none of
the holes. The containers were then placed into a 125 mL plastic Nalgene® container,
para-film side down, and filled with 50 mL of PBS (Figure 3). The lids were screwed on
and the containers were placed inside an incubator at 37°C on a shaker (Stovall – The
Belly Dancer, speed 2). Samples for antibiotic activity were collected at 1, 3, 6, 12, 24,
48, and 72 hours with the PBS solution replaced at every time point.
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Figure 3: Preparation and setup for elution sampling
Vancomycin concentrations were measured using a Thermo Scientific Dionex
UltiMate 3000 Series HPLC and a BDS HYPERSIL reversed-phase C18 column (150 x
4.6 mm). The mobile phase for vancomycin was 30% acetonitrile and 70% potassium
phosphate buffer. Amikacin concentrations were measured by using an amino glycoside
antibiotics detection method [23]. All eluate concentrations were normalized to standard
curves with known concentrations of the antibiotic solution.
Activity
The activity of the vancomycin and amikacin eluted from the pastes and sponge
were determined using zone of inhibition (ZOI) assays (n = 3). Blank paper discs, 6 mm
in diameter, were placed on trypticase soy broth (TSB) agar plates containing a lawn of S.
aureus (ATCC 12598) or P. aeruginosa (ATCC 27317) and were hydrated with 20 μL of
each eluate samples. The TSB agar plates were incubated at 37 °C and removed after 24
hours and photographed. ZOI diameters (mm) were measured.
Enzymatic Degradation
Enzymatic degradation has the similar initial setup as elution other than the paste
was weighed to be approximately 0.666 grams, was hydrated with 5 mL of PBS, and that
the samples were submerged in 50 mL of lysozyme solution (n = 6). Samples were taken
at 1, 2, 3, 4, 5, and 6 day time points. The chicken egg white lysozyme solution (1
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mg/mL in deionized water) was replaced every 24 hours. Once removed from the
incubator, the degraded samples were removed from the solution and transferred to an
aluminum dish and placed in an oven at 80°C for 24 hours to dry. The dried samples
were then weighed and the percent chitosan/PEG paste remaining was calculated. New
samples were used at each time point due to the drying process being destructive to the
paste.
Cytocompatibility
In vitro cytocompatibility was assessed by determining the cell viability of NIH
3T3 cells after being in contact with the evaluated pastes and neutral 1% chitosan
sponges which was a control. The pastes were weighed to be approximately 0.666 grams
and were then hydrated with 5 mL of PBS. Cells were seeded at 1 x 104 cells/mL and
allowed to proliferate overnight on 24-well transparent tissue culture plates in media
under standard cell culture conditions at 37 °C and 5% CO2 atmosphere. The media
consisted of 0.8 mL High Glucose Dulbecco’s Modified Eagle Medium (DMEM) with
10% fetal bovine serum (FBS) and 1% Normocin. Approximately 0.3 mL of each paste
was injected into a cell culture insert with a 3.0 μm pore size membrane, which were
lowered into each well (n = 5/group). Chitosan sponges were hydrated, placed in inserts,
and lowered into wells for the control. After 24 and 72 hours, the inserts containing the
paste were removed and Promega Cell Titer-Glo Luminescent Cell Viability assay was
used to determine cell viability by measuring luminescence at 590 nm and compared to a
standard curve.
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Injectability
Injectability of the paste variations was compared by ejecting the paste from a
standard 25 mL repeater pipette syringe with a modified 3.25 mm diameter tip opening
with empty syringes used for control (n = 3). The paste was weighed approximately to be
0.8 grams and hydrated in a syringe with 6 mL of PBS. Each syringe was fixed into an
Instron Universal Testing Machine with a 5 kN load cell, automated by Instron’s Bluehill
2 (v2.13) software, which compressed the syringe plunger at 1 mm/sec to fully eject the
chitosan paste from the syringe and recorded the maximum ejection force for
comparison.
In Vivo Biocompatibility Assessment Rat Tibia Model (Proof of Principle)
This study assessed the three paste variations with neutral 1% chitosan sponge as
the control. The pastes were weighed to be approximately 0.666 grams and both the
pastes and sponge were hydrated with 5 mL of PBS. The rats (Wistar rats, male) were
anesthetized with isoflurane and anesthesia (UofM – IACUC 0758). The right hind limb
was shaved and scrubbed with betadine and isopropanol. An approximate incision of 10
mm was made with a #10 scalpel blade on the mediolateral surface of the leg and the
muscle tissue was reflected to expose the proximal tibial surface which was roughened
slightly and the bone site marked for identification. The rats then received implanted
paste or sponge respective to their group (n = 3/group). Approximately 0.2 mL of paste
was injected into each defect site. Sutures were used to close tissue over the defect
followed by a cyanoacrylate application. The rats were placed on heating pads and
monitored until they were awake and active. For two days or longer, the rats received an
injection of Rimadyl for pain management and were checked daily for redness and
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swelling. At sacrifice (after 7 days), the implant region, including the tibia and
surrounding tissue, were excised and placed in 10% neutral formalin before undergoing
histological processing with paraffin and/or plastic embedding. Slices were taken
perpendicular to the defect as illustrated in Figure 4.

Figure 4: Illustration of slide preparation from histology
These slices were then stained with hematoxylin and eosin (H & E) and the tissue
response and amount of remaining paste will be determined and quantified by blinded
reviewers. The histology will be ranked on a scoring system of 0-5 (0 – no inflammation,
5 – severe inflammation) [36].
Functional Animal Model: Infection Prevention in a Mouse Pin Model (Proof of
Principle)
The paste types evaluated were 1%:1%, 1%:0.5%, 50:50 and the sponge control
(neutral 1% chitosan sponge) all hydrated with an antibiotic solution, a combination of
vancomycin and amikacin (10 mg/ml each), and then a 1%:0.5% paste group hydrated
with PBS also used for a control (UAMS – IACUC 3579). The pastes were weighed to
be approximately 0.666 grams and both the pastes and the sponge were hydrated with 5
mL of solution. NIH-Swiss mice, 5-8 weeks old, were anesthetized with Isoflurane and
Avertin (0.4-0.6 mg/gm) and the adequacy of the anesthesia was confirmed by the toe
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pinch reflex and the reaction to light shined in the mice eyes. The left leg was cleaned
with povidine iodine and rinsed with 70% ethanol. An incision was made at the knee and
a femoral pin (sterile 0.25 mm insect pins) was surgically implanted as seen in Figure 5.

Figure 5: Image showing location and placement of insect pin inside the mouse femur.
The pin was then inoculated with 2 microliters of cultures of UAMS-1 strain of S. aureus,
a clinical isolate obtained from an osteomyelitis patient [S. aureus (ATCC 12598)]. The
paste was applied immediately after the implantation of the pin through injection of a
volume around 0.05 mL or the neutral sponges were placed adjacent to the pin (n =
3/group). After suturing, the mice were returned to their cages, monitored daily.
Animals were sacrificed 7 days after the treatment and the left femur was removed. The
soft tissue was then dissected from the bone and the femur was cut into small pieces,
placed in a sterile saline and then homogenized. The homogenates were diluted, plated
on agar plates, and the viable microbial colonies were counted along with the colonies
remaining on the pin.
Results
In Vitro Antibiotic Elution and Antibacterial Activity
All paste formulations released steady concentrations above minimum inhibitory
concentration (MIC) of amikacin and vancomycin (both loaded at 10 mg/mL each) over
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the 72 hour in vitro elution as compared to the sponge which released drugs in a typical
burst fashion. In Figures 6 and 7, the elution graph for amikacin and vancomycin can be
found, respectively. A two-way ANOVA test was used followed by a Tukey test to test
for significant differences.

Figure 6: Elution graph for amikacin (n = 3). (A significant difference is found whenever
p < 0.05, * - significant difference between the 1%:1% and the 50:50 pastes, # significant difference between the 1%:0.5% and 50:50 pastes, ᶲ - significant difference
between the neutral 1% sponge and the 1%:1% paste, α – significant difference between
the neutral 1% sponge and the 1%:0.5% paste, γ – significant difference between the
neutral 1% sponge and the 50:50 paste)
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Figure 7: Elution graph for vancomycin (n = 3). (A significant difference is found
whenever p < 0.05, * - significant difference between the 1%:1% and 1%:0.5% pastes, # significant difference between the neutral 1% sponge and the 1%:1%, 1%:0.5%, and
50:50 pastes, ᶲ - significant difference between the neutral 1% sponge and the 50:50
paste)
Both vancomycin and amikacin were shown to be eluted and active through the
72 hour time point. Elution was measurably higher for vancomycin and amikacin in
paste after 10 hours in comparison to the neutral sponge. These results were tested by
performing a zone of inhibition (ZOI) test and the results can be found in Table 2. The
ZOI tests also illustrated an increase in inhibition for paste against P. aeruginosa from
hours 24 through 72. Even though the elution graph for the neutral 1% sponge showed a
higher elution rate of amikacin from 24 through 72 hours, the activity results from the
same eluates showed that there was no active release of amikacin.
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Table 2: Zone of inhibition antibacterial activity results reported as the average ±
standard deviation of the inhibited growth diameter using a solution combination of
vancomycin and amikacin antibiotic eluates against (A) S. aureus and (B) amikacin
antibiotic eluates against P. aeruginosa from 1%:1%, 1%:0.5%, and 50:50 chitosan paste
formulations after 24 hours of direct contact (n = 3). (A significant difference is found
whenever p < 0.05, # - significant difference between the 1%:0.5% and 50:50 pastes, ᶲ significant difference between the 1%:1% and 1%:0.5% pastes, α – significant difference
between the sponge and the 1%:1% paste, γ – significant difference between the sponge
and the 1%:0.5% paste, β – significant difference between the sponge and the 50:50
paste)

S. aureus Zone of Inhibition Diameter (mm), n = 3

A
Sample
Groups
1%:1%
1%:0.5%
50:50
Neutral 1%
Sponge

Eluate Sampling Time Points (hours)
1
16.33 ±
0.57α
15.66 ±
1.15γ
14.33 ±
0.57β
19.66 ±
0.58αγβ

3

6

14.66 ±
0.57
16.33 ±
0.57
15.33 ±
0.57
15.66 ±
0.58

14.66 ±
0.57
16.0 ±
1.73#γ
13.33 ±
0.57#
13.33 ±
0.58γ

12
14.0 ±
2.0α
14.66 ±
0.57γ
14.66 ±
0.57β
10.66 ±
1.53αγβ

24
15.0 ±
1.0α
14.33 ±
0.57γ
15.33 ±
0.57β
8.0 ±
1.0αγβ

48
15.0 ±
0.0α
14.0 ±
1.0γ
13.0 ±
0.0β
4.0 ±
3.46αγβ

72
13.66 ±
0.57α
12.33 ±
1.15γ
11.66 ±
0.57β

24
11.66 ±
1.52α
10.33 ±
0.57γ
11.66 ±
0.57β

48
9.66 ±
1.52α
8.66 ±
1.52γ
11.33 ±
1.15β

72
7.33 ±
1.15α
6.66 ±
0.57γ
6.33 ±
0.57β

0αγβ

0αγβ

0αγβ

0αγβ

P. aeruginosa Zone of Inhibition Diameter (mm), n = 3

B
Sample
Groups
1%:1%
1%:0.5%
50:50
Neutral 1%
Sponge

Eluate Sampling Time Points (hours)
1
13.33 ±
0.57α
11.66 ±
1.15#γ
14.66 ±
0.57#β
18.33 ±
0.58αγβ

3
10.33 ±
0.57α
12.33 ±
0.57
10.33 ±
2.08β
14.0 ±
1.0αβ

6
10.66 ±
1.52ᶲ
13.66 ±
2.08ᶲγ
11.0 ±
0.0
10.0 ±
1.73γ

12
10.0 ±
2.0α
11.66 ±
0.57γ
12.0 ±
1.0β
4.33 ±
3.78αγβ

Enzymatic Degradation
The enzymatic degradation study used lysozyme to evaluate biologically based
degradation of the pastes over the duration of six days. The 1%:1% and 1%:0.5% pastes
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degraded very quickly compared to the 50:50 paste which degraded at a slower rate
(Figure 8).

Figure 8: Enzymatic degradation results for the 1%:1%, 1%:0.5%, and 50:50 pastes
undergoing enzymatic lysozyme degradation (n = 6). (A significant difference is found
whenever p < 0.05, * - significant difference between the 50:50 paste and both the
1%:1% and 1%:0.5% pastes, # - significant difference between the 1%:1% and 1%:0.5%
pastes, ᶲ - significant difference between the 50:50 paste and the 1%:0.5% paste, α –
historical control from Parker et al. [36], chitosan/PEG sponges from studies by Parker et
al. degraded to between 20% and 40% remaining [36])
Cytocompatibility
The results of the cytocompatibility testing are shown in Figure 9. After exposing
cells to the pastes and sponges for 1 and 3 days in culture, the 1%:1% and 50:50 paste
formulations showed a 40-60% higher percent cell viability than the control neutral 1%
sponges and was found to be significantly different on day 1. The 1%:0.5% paste did
show a slight decrease in the percent cell viability during this cytocompatibility study.
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Figure 9: In vitro direct contact cytocompatibility normalized to neutral 1% chitosan
sponge (CS) control reported as the average ± standard deviation of percent cell viability
(n = 5). (A significant difference is found whenever p < 0.05, * - significant difference
between the paste and the control sponge, # - significant difference between the 50:50
and 1%:0.5% pastes)
Injectability
For the injectability comparison test, all pastes were ejected with the 50:50 paste
being used as a control (Figure 10) and then compared to the maximum ejection force
that an individual could achieve of 330 N [3]. The 1%:1% and 1%:0.5% pastes required
less force to inject than the 50:50 paste.
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Figure 10: Injection force results from a modified syringe for the 1%:1%, 1%:0.5%, and
50:50 paste formulations compared against air (n = 3). (A significant difference is found
whenever p < 0.05, * - significant difference when compared to the 50:50 paste)
In Vivo Biocompatibility Assessment Rat Tibia Model (Proof of Principle)
The three formulations of paste along with the neutral 1% sponge were tested for
soft and hard tissue biocompatibility in a rat tibial model. Similar to the
cytocompatibility study, the 1%:1% paste had the greatest biocompatibility when
compared to the 1%:0.5% and the 50:50 pastes with the 1%:0.5% paste having the
highest average amount of inflammation as shown in Figure 11.

30

In Vivo Biocompatibility Assessment Rat Tibia
Model Results
4.5
4

Histology Grade

3.5
3
2.5
2
1.5
1
0.5
0
1%:1%

1%:0.5%

50:50

Neutral 1% Sponge

Figure 11: Rat tibia model results with the neutral 1% sponge as the control (n = 3).
Ranking score: 0 (no inflammation) – 5 (severe inflammation). (Using an ANOVA on
Ranks test, there was found to be no significant differences between the three paste
formulations and the control sponge)
There was no significant difference in inflammation scores found between the chitosan
control sponge and the chitosan paste formulations. Samples of the histology slides that
were used for evaluations can be found in Figure 12.
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Figure 12: Histology slide examples (160X magnification). (A: 1%:1% paste, B:
1%:0.5% paste, C: 50:50 paste, D: neutral 1% sponge)
Functional Animal Model: Infection Prevention in a Mouse Pin Model (Proof of
Principle)
In the infected pin model, the paste formulations and the control sponges hydrated
with the antibiotic solution (vancomycin and amikacin both loaded at 10 mg/mL)
prevented infection and growth of the S. aureus (ATCC 12598). The 1%:0.5% paste
hydrated with PBS was not able to prevent infection from S. aureus. The amount of
microbial colonies remaining from the pin and bone are shown in Figure 13.
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Figure 13: Remaining microbial colonies from the pin and femur (n = 3). (Using
ANOVA on Ranks and Dunnet Post Hoc test a significant difference is found whenever p
< 0.05, * - significant difference when compared to the pastes and sponges hydrated with
the antibiotic solution)
There was a significant difference between the pastes and sponges hydrated with the
antibiotic solution versus the paste hydrated with PBS in the surrounding bone tissue.
From the results, the 1%:1% and 1%:0.5% pastes were shown to be able to elute active
antibiotics to combat contaminating bacteria from causing an infection.
Discussion
Infections in complex musculoskeletal wounds can lead to additional surgeries,
longer treatment and recovery time, costs, and death [16, 13, 7, 3]. In musculoskeletal
wounds where tissue damage and vasculature are compromised, systemic antibiotic
delivery at therapeutic levels can be decreased while locally released antibiotics would be
more effective. With reduced blood flow to the wound, antibiotics can have a difficult
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time reaching the bacteria found in the wound in therapeutic dosages [41, 20]. A device
that is biocompatible, degradable, and can locally release active antibiotics would
improve patient treatment outcomes and require fewer surgeries, and lower the risk of
death [44, 32, 37]. Chitosan sponges and chitosan pastes have been investigated for use
as local antibiotic delivery systems to address problems of infection and traumatic
musculoskeletal injuries [44]. While chitosan delivery devices offer biocompatibility,
degradability, and active antibiotic characteristics, chitosan pastes formulations offera
improved wound coverage allowing for a decreased diffusion distance for the antibiotics
to travel before reaching contaminating bacteria in the wound. Our research questioned
whether different formulations of chitosan paste would offer increased biocompatibility
while maintaining degradability and active antibiotic release over 3 days in order to
develop an improved local drug delivery device to address clinical needs for infection
prevention.
Limitations in this preliminary study include small proof of principle evaluations
in both in vivo biocompatibility and functional infection prevention assessment models.
By increasing the in vivo sample size in both models, an enhanced understanding of the
biocompatibility and infection prevention qualities would be obtained. Using a
musculoskeletal wound in a larger animal in the in vivo functional infection study would
also better represent a bone/soft tissue defect that would reflect a complex
musculoskeletal wound and potential infection variables that are found in a clinical
setting. Our main study objective was to improve biocompatibility, the neutral 1%
chitosan sponge was selected for the control based on past biocompatibility results. A
more representative control for future studies would be to use sponges made of the same
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formulations as the paste to evaluate the difference between the sponge versus the paste.
With the discussed limitations, the PEG blended paste formulations have shown the
potential to be used as local drug delivery devices to treat musculoskeletal wounds and
infections. These blended chitosan-PEG pastes have the ability for improving wound
coverage and reducing antibiotic diffusion distance to the contaminating bacteria in the
wound.
While other chitosan/PEG hydrogels have been shown to release cyclosporine A
and bovine serum albumin in a steady release, these hydrogels were not tested for the
activity or release of bovine serum albumin in vitro [6, 49, 24]. Neutral chitosan and
chitosan/PEG combination sponges have been shown to release an initial burst release of
vancomycin at 7% and 16% respectively but decreased significantly at longer time points
[35]. Chitosan sponges made from acetic and lactic acid loaded with vancomycin
reported that after 1 hour an initial burst of antibiotics was recorded but also experienced
a significant decrease in antibiotics eluted thereafter [32]. Noel et al. found that the
levels of vancomycin and amikacin eluates released from chitosan sponges remained
active through hour 72 and hour 48, respectively. The chitosan/PEG pastes that were
evaluated in this study showed half the amount of initial antibiotic burst release but did
display active antibiotic release through the 72nd hour for both vancomycin and amikacin
in a dual loaded antibiotic approach. Based on the in vivo infected pin model data, we
believe that our pastes will be able to actively release antibiotics and may prevent
infection.
A few published studies regarding the degradation properties of chitosan/PEG
products and hydrogels involved an injectable, chitosan phospholipid blended with lauric
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chloride or lauric aldehyde to help in localized therapeutic applications. Developed by
De Souza et al., the injectable blended hydrogel was tested for degradation in vivo in an
intraperitoneally injected mouse model [14]. The results showed that 7.5% of the
injectable hydrogel was remaining after 4 weeks. Parker et al. used blended
chitosan/PEG sponges (6,000 g/mol PEG) in a degradation comparison study to a neutral
chitosan sponge. After 6 days of lysozyme enzymatic degradation, approximately 60%
of the sponge was remaining. A lower degradation of 0-8% paste remaining was
determined in the studied blended chitosan/PEG pastes. Based on the rapid degradation
of our chitosan/PEG paste formulations found in vitro and in vivo, we can predict that our
paste has the potential to degrade in vivo over several days to weeks.
The literature from past studies for chitosan/PEG hydrogels have reported
acceptable biocompatibility [49, 24, 50]. These results also are comparable to the results
found from testing performed on chitosan/PEG sponges and various chitosan hydrogels
[35, 14, 46]. Results found from in vivo studies include immediate inflammation, tissue
encapsulation from an implanted hydrogel, moderate inflammation from chitosan/PEG
devices, and no inflammatory response from various hydrogels [24, 14, 50, 45, 27]. The
evaluated blended chitosan/PEG paste formulations in our study received similar cellular
response to that of the neutral 1% chitosan sponge in vitro which is comparable to the
studies mentioned. From the in vivo biocompatibility study, our pastes elicited a minimal
to moderate inflammatory response. From our results and past studies evaluating
chitosan/PEG devices, our paste formulations would elicit a minimal inflammatory
response when used in a larger animal model.
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In the literature, there are few studies that look into the injectability of a
chitosan/PEG device. Sprayable thermosensitive chitosan/PEG hydrogels were
developed by Wu et al. for nasal drug delivery but they did not explicitly test
injectability. The device in the Wu study were hydrogels being injected from a needle
while our paste was injected from a larger cannula device [50]. These researcher’s
studies do not directly reflect our procedures because currently there is not a standardized
injectability test.
The chitosan/PEG pastes being investigated exhibit more rapid degradation and
similar biocompatibility to other chitosan/PEG devices as well as showing an extended
elution profile of active antibiotics. When tested in vivo in an infected mouse model, the
pastes were proven to be effective in preventing infections and bacterial growth.
Chitosan sponge, while biocompatible and able to elute active antibiotics, is unable to
offer complete wound coverage and leaves a distance for the antibiotics to travel before
reaching the contaminating bacteria. However, chitosan paste is able to migrate into the
wound bed and release antibiotics closer to the bacteria. In conclusion, the 1%:0.5%
blended chitosan/PEG paste offers more ideal characteristics for being used as a local
drug delivery device to deliver active antibiotics to musculoskeletal wounds to prevent
infection and to provide a greater wound coverage.
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CHAPTER 4
DISCUSSIONS

This discussion will briefly discuss the data and conclusions from chapter 3 along
with the results from the accelerated degradation and adhesion studies. Detailed
descriptions, results, and discussions from these additional studies can be found
respectively in Appendices C and D.
Infections in complex musculoskeletal wounds can lead to additional surgeries,
longer treatment and recovery time, costs, and death [16, 13, 7, 3]. In musculoskeletal
wounds where tissue damage and vasculature are compromised, systemic antibiotic
delivery at therapeutic levels can be decreased while locally released antibiotics would be
more effective in these wounds. With reduced blood flow to the wound, antibiotics can
have difficulty reaching the bacteria found in the wound in therapeutic dosages [41, 20].
Local drug delivery devices assist in this clinical need by being able to be directly applied
to the wound to release antibiotics locally to prevent infections. A device that is
biocompatible, degradable, and can locally release active antibiotics would improve
patient treatment outcomes and require fewer surgeries, decrease additional cost, and
lower the risk of death [44, 32, 37]. Chitosan sponges and chitosan pastes were
developed to have greater biocompatibility and degradability [44]. While both chitosan
sponge and paste local delivery devices offer biocompatibility, degradability, and active
antibiotic characteristics, the chitosan paste offers a greater wound coverage allowing for
a decreased diffusion distance for the antibiotics to travel before reaching contaminating
bacteria in the wound. Our research questioned whether if lowering the acetic acid
concentration in chitosan/PEG paste would offer increased biocompatibility while
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maintaining degradability and active antibiotic release in order to develop an improved
local drug delivery device to address clinical needs for infection prevention.
Limitations in this preliminary study include a small proof of principle
evaluations in both in vivo biocompatibility and functional infection prevention
assessment models. By increasing the in vivo sample size in both models, an enhanced
understanding of the blended pastes’ biocompatibility and infection prevention qualities
would be obtained. Using a larger musculoskeletal wound in a larger animal in the in
vivo functional infection study and would also better represent a bone/soft tissue defect
that would reflect a complex musculoskeletal wound and potential infection variables that
are found in a clinical setting. Since our main study objective was to improve
biocompatibility, the neutral 1% chitosan sponge was selected for the control based on
past biocompatibility results. A more representative control for future studies would be
to use sponges made of the same formulations as the paste to evaluate the difference
between the sponge versus the paste. With the discussed limitations to these preliminary
studies, the PEG blended paste formulations have shown the potential to be used as local
drug delivery devices to treat musculoskeletal wounds and infections. These blended
chitosan-PEG pastes have the ability for improving wound coverage and decreasing
antibiotic diffusion distance to the contaminating bacteria in the wound.
While other chitosan/PEG hydrogels have been shown to release cyclosporine A
and bovine serum albumin in a steady release, these hydrogels were not tested for the
activity or release of bovine serum albumin in vitro [6, 49, 24]. Neutral chitosan and
chitosan/PEG combination sponges have been shown to release an initial burst release of
vancomycin at 7% and 16% respectively but decreased significantly at longer time points
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[35]. Chitosan sponges made from acetic and lactic acid loaded with vancomycin
reported that after 1 hour an initial burst of antibiotics was recorded but also experienced
a significant decrease in antibiotics eluted thereafter [32]. Noel et al. found that the
levels of vancomycin and amikacin eluates released from chitosan sponges remained
active through hour 72 and hour 48, respectively. The chitosan/PEG pastes that were
evaluated in this study showed half the amount of initial antibiotic burst release but did
display active antibiotic release through the 72nd hour for both vancomycin and amikacin
in a dual loaded antibiotic approach above the minimum inhibitory concentration (MIC).
Based on the in vivo infected pin model data, we believe that our pastes will be able to
actively release antibiotics and may prevent infection.
A few published studies regarding the degradation properties of chitosan/PEG
products and hydrogels involved an injectable, chitosan phospholipid blended with lauric
chloride or lauric aldehyde to help in localized therapeutic applications. Developed by
De Souza et al., the injectable blended hydrogel was tested for degradation in vivo in an
intraperitoneally injected mouse model [14]. The results showed that 7.5% of the
injectable hydrogel was remaining after 4 weeks. Parker et al. used blended
chitosan/PEG sponges (6,000 g/mol PEG) in a degradation comparison study to a neutral
chitosan sponge. After 6 days of lysozyme enzymatic degradation, approximately 60%
of the sponge was remaining. A lower degradation of 0-8% paste remaining was
determined in the studied blended chitosan/PEG pastes. Based on the rapid degradation
of our chitosan/PEG paste formulations found in vitro and in vivo, we can predict that our
paste has the potential to degrade in vivo over several days.
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The literature concerning in vitro biocompatibility of chitosan/PEG hydrogels
have been reported that the hydrogels do not cause cytotoxicity and are biocompatible
[49, 24, 50]. These results also are comparable to the results found from testing
performed on chitosan/PEG sponges and various chitosan hydrogels [35, 14, 46]. Results
found from in vivo studies offer more variance from immediate inflammation and tissue
encapsulation from an implanted hydrogel, to moderate inflammation from chitosan/PEG
devices, to no inflammatory response from various hydrogels [24, 14, 50, 45, 27]. The
evaluated blended chitosan/PEG paste formulations developed received similar cellular
response to that of the neutral 1% chitosan sponge in vitro which is comparable to the in
vitro studies mentioned. From the in vivo biocompatibility study, our pastes elicited a
minimal to moderate inflammatory response. Based on our results and past studies
evaluating chitosan/PEG devices, our paste formulations would elicit a minimal
inflammatory response when used in a larger animal model.
In the literature, there are few studies that look into the injectability of a
chitosan/PEG device. Sprayable thermosensitive chitosan/PEG hydrogels were
developed by Wu et al. for nasal drug delivery but they didn’t explicitly test injectability.
Although, the device in the Wu study were hydrogels being injected from a needle while
our paste was injected from a larger cannula device [50]. These researcher’s studies do
not directly reflect our procedures because currently there is not a standardized
injectability test.
Additional blended paste evaluations which were not included in Chapter 3,
including accelerated degradation and adhesion, are listed below.
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The test used to achieve the accelerated degradation results was used from Martin
et al. and used a cobalt dichloride solution to degrade the chitosan [29]. This study is
more commonly used for polyurethane devices while we adapted methods for a
degradation study to develop a rapid ranking assessment before conducting the enzymatic
degradation. The lysozyme based enzymatic degradation of the pastes would
theoretically degrade in a similar mechanism as in a musculoskeletal wound. The
rankings of paste degradation were found to be consistent with the enzymatic degradation
study showing that the 1%:1% paste degraded the quickest and the 1%:0.5% and 50:50
pastes remained through longer time points.
To test the adhesivity of chitosan/PEG devices, we have not found an effective
and accepted standard test to evaluate this characteristic. Changes were made from
Rhodes et al. adhesivity testing where we directly measured the migration of the
chitosan/PEG devices so that each type could be compared against a neutral 1% chitosan
sponge control [39]. The 50:50 combination paste results were consistent with the results
from the Rhodes study while both the 1%:1% and 1%:0.5% pastes migrated on average 1
inch and 0.6 inches respectively.
The chitosan/PEG pastes being investigated exhibit quicker degradation and
similar biocompatibility to other chitosan/PEG drug delivery devices as well as showing
a desirable elution profile of active antibiotics. A comparison between each paste
formulation and sponge tested can be seen in Table B.
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Table B: Comparison between paste formulations and neutral sponge. (‘
results, ‘–’- acceptable results, ‘X’ – less than desirable results)

’ - improved

When tested in vivo in an infected mouse model, the pastes were proven to be
effective in preventing infections and bacterial growth. Chitosan sponge, while being
biocompatible and able to elute active antibiotics, is unable to offer complete wound
coverage and leaves a distance for the antibiotics to travel before reaching the
contaminating bacteria. However, chitosan paste is able to migrate into the wound bed,
provide a greater wound coverage, and release antibiotics closer to the bacteria. In
conclusion, the 1%:1% and 1%:0.5% blended chitosan/PEG pastes can be used as a local
drug delivery device to deliver active antibiotics to musculoskeletal wounds to prevent
infection and to provide a greater wound coverage.
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CHAPTER 5
CONCLUSIONS

Based on the blended chitosan/PEG pastes evaluated in the studies presented in
this paper, both blended pastes offer different advantages when used as a local drug
delivery device. While starting off with more acidic chitosan sponges made by Rhodes et
al. and Smith et al., the 1%:1% and 1%:0.5% pastes offered similar biocompatibility
results as the less acidic 50:50 combination paste from Rhodes’ studies.[39, 42] The
main goal of this project was to improve biocompatibility compared to the 50:50 chitosan
paste. Though our goal was not achieved, we were able to achieve comparable
biocompatibility by decreasing the acidity of the paste to make a less acidic sponge and
using 8,000 g/mol PEG in place of the 6,000 g/mol PEG. Also by decreasing the acidity
of the pastes and eliminating the need for combining acidic and neutral sponges, the
fabrication process was shortened and requires only one lyophilization to manufacture the
final product. Because of the composition of the 1%:1% and 1%:0.5% pastes, the
blended chitosan/PEG pastes degrade in half the time as the 50:50 paste which has an
extended enzymatic degradation time frame. Also from the composition of the pastes,
the 1%:1% and 1%:0.5% pastes offer an injectability force of under 50 N compared to the
approximately 150 N force needed for the 50:50 paste. While there is a difference in
composition, all three pastes are able to elute active antibiotics throughout the 72 hours of
the study with the 50:50 paste eluting the most followed by the 1%:0.5% paste.
Based on the results from the studies as well as the in vivo models, the 1%:0.5%
paste has more suitable characteristics for a local drug delivery device from the
evaluation of the tests between the chitosan pastes. While the 50:50 paste has a slightly
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better biocompatibility and the 1%:1% paste exhibits quick enzymatic degradation, the
1%:0.5% paste has similar biocompatibility to past acidic pastes, a decreased fabrication
time, and offers improved injectability from the 50:50 paste as well as better adhesive
properties and elution results from the 1%:1% paste.
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CHAPTER 6
FUTURE WORK

Even though the 1%:1% and 1%:0.5% chitosan/PEG pastes have been shown to
have improved biocompatibility and active eluted antibiotics, additional expanded in vivo
studies are needed. Animal models with a larger sample size will help further solidify
and confirm the biocompatibility, elution, and functional properties of the chitosan/PEG
pastes.
Another aspect that needs to be evaluated is the type of sponge used for the
control throughout the in vivo and in vitro studies. The main goal of this research was to
improve the biocompatibility of the chitosan pastes so the neutral 1% chitosan sponge
was selected for the control due to its known biocompatibility. While the neutral sponge
is a great control for biocompatibility studies, a better control is needed for comparison of
each type of paste. Using a sponge made to the same specifications of the 1%:1% and
1%:0.5% pastes will allow us to evaluate how the formulations work in sponge versus
paste form.
Other future work can include looking into different combinations of chitosan
versus PEG to determine which formulations work best for elution, degradation, and
biocompatibility. Using chitosan with different degrees of deacetylation and molecular
weight could be evaluated to see how those specifications change biocompatibility. With
both of the 1%:1% and 1%:0.5% pastes having quick degradations over the course of the
enzymatic degradation study, a paste with a decreased concentration of PEG and a higher
concentration of chitosan may be able to provide a slower degradation to allow the paste
to stay in vivo longer to deliver antibiotics to hopefully prevent musculoskeletal
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infections. Different molecular weights of PEG should also be tested to determine which
weight offers the greatest results for use in a local drug delivery device.
Finally, looking into what can be loaded into the chitosan pastes should be
evaluated like antifungals and growth factors. Antifungals should be loaded into the
pastes and tested to see if the applications for chitosan pastes can be broadened to offer a
greater versatility.
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APPENDIX A: DETAILED MATERIALS AND METHODS FOR CHAPTER 3
Fabrication
All materials were purchased from Fisher Scientific (Pittsburgh, PA) unless
otherwise noted. The chitosan/PEG paste was fabricated using Chitopharm S chitosan
powder (Chitinor AS, Tromsø, Norway) with an 82.46 ± 1.679 degree of deacetylation
and an average molecular weight of 250.6 kDA and/or polyethylene glycol with a
molecular weight of 6,000 g/mol (PEG; Sigma Aldrich, St. Louis, MO). For the neutral
portion of the paste, 0.5% w/v of 6,000 g/mol PEG was dissolved in a 1% v/v acetic acid
in ultrapure water solution and, following dissolution, 0.5% w/v of chitosan was
dissolved in the same solution. The acidic portion of the paste was made in the same
manner, but dissolving only 1% w/v of chitosan in the acetic acid solution. Both solutions
for the neutral and acidic sponge were cast into 500 mL containers at a volume of
approximately 333 mL, frozen overnight at -20 °C, and lyophilized in a benchtop freeze
dryer (LabConco, Kansas City, MO) to create acidic, dehydrated sponges. To obtain the
neutral sponges, they were neutralized in 0.25 M sodium hydroxide (NaOH) and washed
with ultrapure water until a neutral pH was reached, frozen at -20 °C overnight, and
lyophilized again to create the neutral, dehydrated sponges. Both the acidic and neutral
sponges were ground separately into small flakes (≤ .3 cm) and then combined in a 50:50
combination to be used to make the 50:50 paste. The 1%:1% paste formulation was
made by dissolving 1% w/v of 8,000 g/mol PEG into a 0.85% v/v of acetic acid in
ultrapure water solution and then dissolving 1% w/v of chitosan. The solution is then
frozen overnight and then lyophilized and ground up with a coffee grinder. The process
to manufacture the 1%:0.5% paste is the same as the 1%:1% with the exception of the
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amount of PEG being 0.5% w/v of 8,000 PEG. In order to turn the ground sponges into a
paste, the flakes are hydrated with a phosphate buffered saline (PBS) in ultrapure water
solution at 7.5 times the paste’s dehydrated weight. All samples used for biological
testing were sterilized with ethylene oxide (EtO) gas prior to hydration.
Elution
For elution, one study was run and the samples were loaded with a combination of
vancomycin and amikacin both at a 10 mg per mL concentration. The 1%:1%, 1%:0.5%
and 50:50 pastes were hydrated with 5 mL of vancomycin or amikacin and then placed
into a metal, hemispherical container with numerous holes (approximately 1.5 mm in
diameter). Each metal container was then covered with para-film while making sure that
none of the holes were covered. The container was then placed into a 125 mL plastic
Nalgene container, para-film side down, and subsequently filled with 50 mL of 1× PBS.
The lids were screwed and the containers were then placed inside an incubator at 37°C on
a shaker. Samples remained in the incubator at 37 °C until each time point. Samples to
be used for HPLC and antibiotic activity were collected at 1, 3, 6, 12, 24, 48, and 72
hours with the PBS solution completely replaced at every time point (Figure B) (n = 3).
All paste samples used were EtO sterilized.
Vancomycin concentrations were measured using a Thermo Scientific Dionex
UltiMate 3000 Series HPLC and a BDS HYPERSIL reversed-phase C18 column (150 x
4.6 mm). The mobile phase for vancomycin was 30% acetonitrile and 70% potassium
phosphate buffer (0.0124 M KPO4 and 0.0876 M K2PO4). Vancomycin had a 2.637minute retention time using a 1.0 mL/min flow rate with a 209 nm UV detection.
Amikacin concentrations were measured by using an amino-glycoside antibiotics
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detection method [23]. A buffer solution is made with 11.5 mL of .2M acetic acid, 14
mL of .2M phosphoric acid, 12.5 mL of .2M boric acid, and 975 mL of deionized water
and then the pH level brought to 2.7 with sodium hydroxide. Then a formaldehyde
solution is made by mixing 4 grams of para formaldehyde in 100 mL of deionized water
at 60 °C and then adding sodium hydroxide to dissolve the para formaldehyde until
solution is clear. Finally a reaction solution is made by adding 2 mL of the buffer
solution, 1 mL of acetyl acetone, and 10 mL of formaldehyde solution together. Add 1
mL of this reaction solution and 1 mL of the elution sample together and place in an oven
at 100 °C for 20 minutes. After being cooled to room temperature, place 100 μL of
solution into black opaque 96 well plates and read at 410/471 (excitation/emission). The
detection range for this method is 100 μg/mL to 0.0039 μg/mL. All eluate concentrations
for both vancomycin and amikacin were normalized to standard curves with known
concentrations.

Figure B: Steps on how elution samples were prepared and time points were taken
Activity
The antibiotic activity of the vancomycin and amikacin eluted in vitro from the
1%:1%, 1%:0.5%, and 50:50 paste variations were determined using zone of inhibition
(ZOI). On trypticase soy broth (TSB) agar plates, blank discs, 6 mm in diameter, were
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placed on a lawn of S. aureus (ATCC 12598) or P. aeruginosa (ATCC 27317) and were
hydrated with 20 μL of vancomycin or amikacin eluate samples, respectively (n = 3). The
TSB agar plates were incubated at 37 °C and removed after 24 hours where pictures were
taken and ZOI diameters, not including the discs, were measured.
Accelerated Degradation
Accelerated in vitro degradation was assessed by the weight reduction of the
1%:1%, 1%:0.5%, and the 50:50 combination chitosan/PEG paste variations over time.
Dehydrated weights of each EtO sterilized paste combination were recorded prior to
hydration (n = 3). After being hydrated, each 5 mL sample was placed into a metal,
hemispherical container with numerous holes (approximately 1.5 mm in diameter). Each
metal container was then covered with para-film while making sure that none of the holes
were covered. Make up a 0.1M CoCl2 solution by adding 2700 mL of deionized water,
300 mL of 30% hydrogen peroxide, and then 71.37 grams of CoCl2 [29]. The container
was then placed into a 125 mL plastic Nalgene container, para-film side up, and
subsequently filled with 70 mL of the 0.1M cobalt dichloride solution making sure that
each hole was submerged. The lids were screwed on loosely to allow for the release of
gas from the reaction. The containers were then placed inside an incubator at 37°C on a
shaker. Samples remained in the incubator until each time point. Samples were taken at
2, 3, 4, 5, and 18 hour time points. Once removed from the incubator, the degraded
samples were removed from the solution and transferred to an aluminum dish and placed
in an oven at 80°C for 24 hours to dry. The dried samples were then weighed, and the
percent chitosan/PEG paste remaining was calculated by dividing the degraded weight by
the initial weight and then multiplying by 100. New samples were used at each time
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point due to the drying process being destructive to the paste. See Appendix C for results
and statistical data.
Enzymatic Degradation
Enzymatic degradation utilized the same setup as the accelerated degradation
study, with the exception of the EtO sterilized paste combinations being submerged in 50
mL of lysozyme solution instead of 70 mL of cobalt dichloride to simulate how chitosan
degrades in the body (n = 3). The lysozyme solution was 1 mg/mL chicken egg white
lysozyme in ultrapure water. A lysozyme solution was used because in the body
lysozyme is a major component in the degradation of chitosan [48, 9]. Samples were
taken at 1, 2, 3, 4, 5, and 6 day time points and the samples remained within the incubator
until they were taken with the exception of when the lysozyme solution was being
replaced which happened every 24 hours. Once removed from the incubator, the
degraded samples were transferred to an aluminum dish and placed in a vacuum oven at
80 °C for 24 hours to dry. The dried samples were then weighed, and the percent
chitosan/PEG paste remaining was calculated by dividing this dry, degraded weight by
the initial, dehydrated weight and multiplying by 100. Because the drying process was
destructive to the samples, new samples were used for each time point for all three paste
variations.
Cytocompatibility
In vitro cytocompatibility was assessed by determining the cell viability of NIH
3T3 cells after being in contact with the 1%:1%, 1%:0.5%, 50:50 combination
chitosan/PEG pastes and neutral 1% sponges (used as a control). All paste and sponge
samples were EtO sterilized prior to use. Cells were seeded at 1 x 104 cells/mL and
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allowed to proliferate on 24-well transparent tissue culture plates in complete media. The
media consisted of 0.8 mL High Glucose Dulbecco’s Modified Eagle Medium (DMEM)
with 10% fetal bovine serum (FBS) and 1 x Normalin. All of this was done under
standard cell culture conditions at 37 °C and 5% CO2 atmosphere. Approximately 0.3 mL
of each paste ratio was injected into a cell culture insert with a 3.0 μm pore size
membrane, each of which was subsequently lowered into the media of one well (n = 5).
Neutral 1% chitosan sponges were placed in inserts and lowered into wells for the
control. After the plates were incubated for 24 and 72 hours, the inserts containing the
paste were removed and the Promega Cell Titer-Glo Luminescent Cell Viability assay
was used to determine cell viability by measuring luminescence at 590 nm and compared
to a standard curve.
Injection
Injectability of the 1%:1%, 1%:0.5%, and 50:50 chitosan/PEG paste variations
was assessed by ejecting the paste from a standard 25 mL repeater pipette syringe with a
modified 3.25 mm diameter tip opening with empty syringes used for control (n = 3).
Each syringe was loaded with 6 mL of paste and fixed into an Instron Universal Testing
Machine with a 5 kN load cell, automated by Instron’s Bluehill 2 (v2.13) software, which
compressed the syringe plunger at 1 mm/sec to fully eject the chitosan/PEG paste from
the syringe (Figure C). Maximum ejection force was recorded and compared to a
clinically relevant maximum ejection force that an individual could achieve of 330 N [3].
All paste samples used were EtO sterilized.
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Figure C: Injection study setup
Adhesion
To determine the adhesiveness of the paste formulations, porcine cervical
vertebrae were used as representative hard and soft tissues (Kroger, Memphis, TN) and
coated in fetal bovine serum (FBS) to simulate blood-like components. Adhesion was
visually assessed by adhering 5 mL of paste to the FBS coated tissue and timing its
adherence for a minimum of 1 minute (n = 3). Each sample was then doused with 10 mL
of PBS as simulated wound fluid to observe if this would dislodge the paste sample.
Also the slippage distance was recorded using a ruler once the paste was applied and
before the PBS was added. After the PBS was administered, the pastes were evaluated
with the ruler again to record the distance the paste had moved. All paste samples used
were EtO sterilized. See Appendix D for results and statistical data.
In Vivo Biocompatibility Assessment Rat Tibia Model (Proof of Principle)
This study was planned for four treatments. The groups were 1%:1% chitosan
paste, 1%:0.5% chitosan paste, 50:50 chitosan paste, and neutral 1% chitosan sponge
(which was used as the control). There was no antibiotics associated with this study as
we were evaluating the biological response of the bone and surrounding soft tissue to the
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paste formulations and a sponge control. This initial study was a proof of principle study
and only used 25% of the animals planned in the study outline and protocol (12 rats, 3 for
each treatment – IACUC 0758). The rats (Wistar rats, male) were anesthetized with
isoflurane and anesthesia. The right hind limb was shaved and scrubbed with betadine
and isopropanol prior to surgery and 0.05 cc of Rimadyl was used for pain management.
An approximate incision of 10 mm was made using a #10 scalpel blade on the
mediolateral surface of the leg and the muscle tissue was reflected to expose the proximal
tibial surface. In each rat, the surface of the bone was roughened slightly and the bone
site marked for identification. The rats received implanted paste or sponge respective to
their group. Approximately 0.2 mL of paste was injected into each defect site.
Subcutaneous sutures were used to close the soft tissue over the defect and were followed
by cutaneous sutures and cyanoacrylate application. During recovery, the rats were
placed on heating pads and monitored until they awoke and then were returned to their
housing facilities. For two days, longer if needed, the rats received an injection of
Rimadyl for pain management and their surgical sites were checked daily for redness and
swelling. At sacrifice (after 7 days), the implant region, including the tibia and
surrounding tissue, were excised and placed in 10% neutral formalin. The samples were
then shipped, soaked in formalin, to University of Alabama at Birmingham where they
underwent histological processing with paraffin and/or plastic embedding and were sliced
and plated. Slices were taken perpendicular to the defect as illustrated in Figure D.
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Figure D: Illustration of slide preparation from histology
These slices were then stained with hematoxylin and eosin (H & E) and the tissue
response, amount of inflammation, and amount of remaining paste was determined and
quantified by blinded reviewers. The histology was ranked on a scoring system of 0-5 (0
– no inflammation, 5 – severe inflammation) [36].
Functional Animal Model: Infection Prevention in a Mouse Pin Model (Proof of
Principle)
For this animal model, there were 5 groups with 3 mice in each group. Each type
of paste (1%:1%, 1%:0.5%, 50:50) and the sponge control (neutral 1% chitosan sponge)
were tested with a antibiotic solution combination of vancomycin and amikacin (10
mg/mL each) and then a 1%:0.5% paste group was tested with PBS (UAMS – IACUC
3579). NIH-Swiss mice, 5-8 weeks old, were anesthetized with Isoflurane plus Avertin
(0.4-0.6 mg/gm) and the adequacy of the anesthesia was confirmed by the toe pinch
reflex and the reaction to light shined in the mice eyes. Only after being sure of
significant, deep anesthesia did procedures continue. The left leg of each mouse was
cleaned with povidine iodine and rinsed with 70% ethanol. An incision, approximately 5
mm, was made at the knee and a femoral pin (sterile 0.25 mm insect pins) was then
surgically implanted into the left leg of each mouse. After insertion, the pin was
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inoculated with 2 microliters of cultures of UAMS-1 strain of S. aureus, a clinical isolate
obtained from an osteomyelitis patient [S. aureus (ATCC 12598)]. The paste, implanted
through injection, was applied immediately after the implantation of the pin with a
volume around 0.05-0.08 mL and with the neutral sponges being placed adjacent to the
pin. After the incisions had been sewn up, the mice were returned to their cages and
separated into their specific groups. The mice were monitored daily and any that
appeared moribund were euthanized using CO2. Animals were sacrificed 7 days after the
treatment and the left femur was removed. The soft tissue was dissected from the bone
and the femur was cut into small pieces and placed in a sterile saline. The femur
segments were then homogenized and the homogenates were diluted, plated on agar
plates, and the number of viable microbial colonies were counted.

62

APPENDIX B: ZONE OF INHIBITION PHOTOGRAPHS
Amikacin/Vancomycin Activity Results
50:50

1%:1%

1%:0.5%

1% Sponge

Figure E: Zone of inhibition photographs for the antibiotic combination of vancomycin
and amikacin loaded chitosan/PEG paste and neutral 1% chitosan sponges over 72 hours
tested against P. aeruginosa. (n = 3).
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50:50

1%:1%

1%:0.5%

1% Sponge

Figure F: Zone of inhibition photographs for the antibiotic combination of vancomycin
and amikacin loaded chitosan/PEG paste and neutral 1% chitosan sponges over 72 hours
tested against S. aureus. (n = 3).
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APPENDIX C: ACCELERATED DEGRADATION DATA
Materials and Methods
Accelerated degradation has the similar initial setup as elution other than the paste
was weighed to be approximately 0.666 grams and were hydrated with 5 mL of PBS (7.5
x the dehydrated paste weight). Make up a 0.1M CoCl2 solution by adding 2700 mL of
deionized water, 300 mL of 30% hydrogen peroxide, and then 71.37 grams of CoCl2.
Then the plastic containers filled with 70 mL of the 0.1M cobalt dichloride solution with
the lids were loosely placed to allow for the reactions release of gas (n = 3). Samples
were taken at 2, 3, 4, 5, and 18 hour time points. At the time points, the samples were
removed from the solution, transferred to an aluminum dish, and placed in an oven at
80°C for 24 hours. The samples were then weighed, and the percent chitosan/PEG paste
remaining was calculated in relation to the initial weight.
Results
From the accelerated degradation study, the 1%:1% paste degraded prior to the
first time point taken at hour 2. Both the 50:50 and the 1%:0.5% pastes showed a more
gradual decline in percent weight degradation but were both completely gone by 18 hours
(Figure G).
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Figure G: Accelerated degradation results for the 1%:1%, 1%:0.5%, and 50:50 paste
formulations (n = 3). (A significant difference is found whenever p < 0.05, * - significant
difference between the 1%:1% paste and both the 1%:0.5% and 50:50 pastes)
Discussion
The 1%:1% paste formulation rapidly degraded away leaving no part of the initial
paste behind before the 2 hour time point due to its low viscosity. On the other hand, the
1%:0.5% and 50:50 pastes degraded in a more linear pattern and there was no significant
difference found between them. The 1%:0.5% and 50:50 paste were able to remain
longer because the pastes themselves are more compact and tend to not disassociate as
quickly as the 1%:1% paste. If the situation calls for a quick degradation, the 1%:1%
paste would be the ideal candidate. Although if the paste is needed in the wound for a
longer duration then the 1%:0.5% and the 50:50 paste formulations would make for the
better choice.
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APPENDIX D: ADHESION DATA
Materials and Methods
To determine the adhesiveness of the paste formulations, porcine cervical
vertebrae were used as representative hard and soft tissues (Kroger, Memphis, TN) and
coated in fetal bovine serum (FBS) to simulate blood-like components. Adhesion was
visually assessed by adhering 5 mL of paste to the FBS coated tissue and timing its
adherence for a minimum of 1 minute (n = 3). Each sample was then doused with 10 mL
of PBS as simulated wound fluid to observe if this would dislodge the paste sample.
Also the slippage distance was recorded using a ruler once the paste was applied and
before the PBS was added. After the PBS was administered, the pastes were evaluated
with the ruler again to record the distance the paste had moved (Figure H). All paste
samples used were EtO sterilized.

Figure H: Steps for obtaining adhesion results
Results
During the adhesion study, both the 50:50 and 1%:0.5% paste formulations
exhibited minimal or hardly noticeable migration during the minute prior to being doused
in PBS. However, the 1%:1% paste immediately began to migrate down the tissue. After
the addition of the PBS, the 50:50 paste remained unmoved while the 1%:0.5% paste
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began to migrate down. The 1%:1% paste showed the most migration and potentially
could have migrated further but the amount of tissue used was limited. The 1%:0.5%
paste migrated on average around 0.6 in. while the 50:50 paste remained adhered to its
initial application point (Figure I). The statistical analysis was done using a one-way
ANOVA test followed by a Tukey test.

Figure I: Adhesion results showing the migration distances between the 1%:1% paste,
1%:0.5% paste, 50:50 paste and the neutral 1% chitosan sponge used for control (n = 3).
(A significant difference is found whenever p < 0.05, * - significant difference between
the signified paste/sponge type versus the 1%:1% paste formulation)
Discussion
The adhesion test aims to evaluate how well the pastes adhere to tissue. The
50:50 paste when doused with PBS remained unmoved. Being less viscous the 1%:0.5%
migrated down the tissue shortly after the PBS was administered. The 1%:1% paste is
the least viscous of the three paste variations and began migrating soon after being
applied to the tissue prior to being rinsed over with PBS. The neutral sponge migrated
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very minimally, holding in place better than both the 1%:1% and 1%:0.5% paste
formulations.
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APPENDIX E: PRELIMINARY CHITOSAN/PEG PASTE REFINEMENT DATA
Objective
The goal of these experiments was to evaluate if through accelerated degradation
and cytocompatibility studies the use of the 1%:1% and 1%:0.5% paste formulations
were viable for further testing.
Materials and Methods
Appendix A is where detailed steps for fabrication, accelerated degradation, and
cytocompatibility can be found used to test these paste formulations.
Fabrication
The acidic 1% chitosan and neutral 1% chitosan/PEG products were ground
separately into a powder, and combined into a 50:50 acidic to neutral ratio while the
1%:1% and 1%:0.5% products where ground straight into a powder. A 1× phosphate
buffered saline (PBS) in deionized water solution at 7.5 times the paste’s dehydrated
weight was added to the dehydrated chitosan powder to form a hydrated chitosan/PEG
paste (formulations can be seen in Table C). For these preliminary studies none of the
pastes were sterilized.
Table C: Compositions of the sponges used to make the 50:50, 1%:0.5%, and 1%:1%
pastes
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Initial Cytocompatibility
In vitro cytocompatibility was assessed by determining the cell viability of normal
human dermal fibroblast (NHDF) cells after being in contact with the 1%:1%, 1%:0.5%,
and 0.5%:0.5% combination chitosan/PEG paste variations with future plans for
replication. Cells were seeded at 1 x 104 cells/mL and allowed to proliferate on 12-well
transparent tissue culture plates in complete media and approximately 0.5 mL of each
paste ratio was injected into a cell culture insert. After the plates were incubated for 24
and 72 hours, the inserts containing the paste were removed and the Promega Cell TiterGlo Luminescent Cell Viability assay was used to determine cell viability by measuring
luminescence at 590 nm. Luminescence values were normalized to untreated NHDF
cells on tissue culture plastic (TCP) at each time point to determine percent cell viability.
Plans are to replicate study to solidify results.
Initial Accelerated Degradation
Preliminary in vitro degradation was assessed by weight reduction of the 50:50,
1%:1%, and 1%:0.5% paste formulations over time (n = 3). Samples were taken at 2, 3, 4,
5, and 18 hour time points with plans for replication along with an enzymatic
degradation. The percent of paste remaining was calculated by dividing the dry,
degraded weight by the initial, dehydrated weight and multiplying by 100. New samples
were used for each time point because the drying process is destructive to the paste. A
replicate experiment with lysozyme is needed to imitate what happens in vivo.
Statistical Analysis
Accelerated degradation and cytocompatibility testing were analyzed using twoway Analysis of Variance (ANOVA) followed by Holm-Sidak post hoc tests. All results
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are presented as the average ± standard deviation and evidence of a statistically
significant difference occurred when p < 0.05.
Results
Initial Cytocompatibility
Percent cell viability results for the 1%:1%, 1%:0.5%, and 50:50 are shown in the
figure below. While all samples showed a significant increase in cell growth over time,
the percent cell viability of each paste combination significantly decreased from 24 to 72
hours. The 1%:1% paste combination showed the highest cell growth over time as well as
the highest percent cell viability over the 24 and 72 hours (Figure J). The data was
analyzed by using a two-way ANOVA test and there was a statistically significant
difference (P = 0.049) found. A Holms-Sidak test was used to find between which
groups that the difference occurred. By switching to the less conservative Tukey test, the
statistically significant difference was found to be between the untreated cells and the
0.5%:0.5% paste configuration (P = 0.048).
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Figure J: In vitro direct contact biocompatibility normalized to tissue culture plastic
(TCP) control reported as the average ± standard deviation of percent cell viability for
1%:1%, 1%:0.5%, and 0.5%:0.5% combination chitosan/PEG paste (CPP) variations
after 24 and 72 hours (n = 5).
Initial Accelerated Degradation
Figure H, below, shows the percentage of the chitosan/PEG paste combinations
remaining for all three variations between the 2, 3, 4, 5, and 18 hour time points. The
1%:1% paste was fully degraded even before the 2 hour time interval. That specific paste
is less viscous than the other paste combinations tested which allowed for its quick
degradation. The 1%:0.5% paste showed a steady increase in degradation throughout the
study while the 50:50 paste increased slowly before becoming completely degraded
(Figure K). All of these paste combinations were not sterilized for this experiment and
may behave differently after sterilization. Using a two-way ANOVA test a statistically
significant difference (P = 0.033) was found. The Holms-Sidak test found that there was
a statistically significant difference was between the 1%:0.5% and the 1%:1% paste
combinations (P = 0.038).
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Figure K: In vitro enzymatic accelerated degradation reported as the average ± standard
deviation of weight percent remaining of the sample for 1%:1%, 1%:0.5%, and 50:50
combination chitosan/PEG paste (CPP) variations over 18 hours (n = 3). The 50:50 paste
was used as a control.
Discussion
The degradation results showed that each of the three paste combinations will
degrade over time with the 1%:1% chitosan/PEG configuration degrading the best
followed by the 50:50 and the 1%:0.5% respectively. From the biocompatibility results,
the 1%:1% paste exhibited the greatest cell viability. The 1%:0.5% showed better
percent cell viability than the 0.5%:0.5% paste after the first day but they were similar
after the third day. Based on these results, research should be continued using the
1%:1%, 1%:0.5%, and 50:50 chitosan/PEG paste variations.
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APPENDIX F: PRELIMINARY ELUTION AND ZONE OF INHIBITION
PHOTOGRAPHS
Materials and Methods
Elution studies were run with vancomycin and then with amikacin. The pastes
were hydrated with 6 mL of 5 mg/mL of vancomycin or amikacin in PBS and then placed
into a metal, hemispherical container with numerous holes (approximately 1.5 mm in
diameter), and covered with para-film while covering none of the holes. The containers
were placed into a 125 mL plastic Nalgene container, para-film side up, and filled with
50 mL of 1× PBS. The lids were screwed on and the containers were then placed inside
an incubator at 37°C on a shaker. Samples for antibiotic activity were collected at 1, 3, 6,
12, 24, 48, and 72 hours with the PBS solution replaced at every time point.
Vancomycin and amikacin concentrations were measured utilizing a BDS
HYPERSIL reversed-phase C18 column (150 x 2.1 mm) from Thermo Scientific. The
mobile phase for vancomycin was 30% acetonitrile and 70% sodium phosphate buffer
(0.0124 M NaPO4 and 0.0876 M Na2PO4) and the mobile phase for amikacin was 80% to
10% of a buffer solution (.2 M acetic acid, .2 M phosphoric acid, .2 M boric acid with a
pH of 2.7) and then with 20% to 90% of acetonitrile with the gradient happening over an
eight-minute time frame.
In Vitro Antibiotic Elution and Antibacterial Activity Results
All paste formulations released steady concentrations of amikacin and
vancomycin over the 72 hour in vitro elution. Vancomycin had a 2.637-minute retention
time using a 1.0 mL/min flow rate with a 209 nm UV detection. Amikacin had a 1.532minute retention time using a 1.0 mL/min flow rate with a 450 nm fluorescence detection.
All eluate concentrations were normalized to standard curves with known concentrations
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of vancomycin and amikacin (Figures L and M). A one-way ANOVA test was used
followed by a Tukey test.

Figure L: Elution graph for amikacin. (A significant difference is found whenever p <
0.05, * - significant difference between the 1%:1% and 1%:0.5% pastes, # - significant
differences between the 50:50 and 1%:1% pastes, ᶲ - significant difference between the
50:50 and 1%:0.5% pastes)

Figure M: Elution graph for vancomycin. (A significant difference is found whenever p <
0.05, * - significant difference between the 1%:1% and 1%:0.5% pastes, # - significant
differences between the 50:50 and 1%:1% pastes, ᶲ - significant difference between the
50:50 and 1%:0.5% pastes)
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Loaded with vancomycin, the pastes remained active all the way through hour 72
with the exception of the 1%:0.5% paste which was active through hour 48. However,
the pastes with amikacin remained active through hour 48 (Table D).
Table D: Zone of inhibition antibacterial activity results reported as the average ±
standard deviation of the inhibited growth diameter using (A) vancomycin antibiotic
eluates against S. aureus and (B) amikacin antibiotic eluates against P. aeruginosa from
1%:1%, 1%:0.5%, and 50:50 chitosan paste formulations after 24 hours of direct contact
(n = 3). (A significant difference is found whenever p < 0.05, * - significant difference
between the 1%:1% and 50:50 pastes, # - significant difference between the 1%:0.5% and
50:50 pastes, ᶲ - significant difference between the 1%:1% and 1%:0.5% pastes)
S. aureus Zone of Inhibition Diameter (mm), n = 3

A
Sample
Groups
1%:1%
1%:0.5%
50:50

Vancomycin Eluate Sampling Time Points (hours)
1
14.6 ±
0.57
12.6 ±
0.57
13.3 ±
1.1

3
15.6 ±
0.57*
13.6 ±
0.57
12.6 ±
0.57*

6
13.3 ±
0.57
14.3 ±
0.57
12.3 ±
0.57

12
11.3 ±
0.57
13.6 ±
0.57
12.0 ±
0.0

24
12.3 ±
0.57
12.0 ±
1.0
12.6 ±
0.57

48
10.6 ±
1.5
8.0 ±
1.7#
12.3 ±
0.57#

72
6.3 ±
4.6*ᶲ
0#ᶲ
12.0 ±
0.0*#

P. aeruginosa Zone of Inhibition Diameter (mm), n = 3

B
Sample
Groups
1%:1%
1%:0.5%
50:50

Amikacin Eluate Sampling Time Points (hours)
1
12.3 ±
0.57
11.3 ±
0.57#
13.3 ±
0.57#

3
14.3 ±
0.57*ᶲ
12.3 ±
0.57ᶲ
10.6 ±
0.57*

6
13.0 ±
1.0*
11.3 ±
0.57
10.6 ±
0.57*

12
10.6 ±
0.57
12.3 ±
0.57
11.3 ±
0.57
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24
11.0 ±
1.0
10.3 ±
0.57#
12.6 ±
0.57#

48
5.6 ±
0.57*ᶲ

72

3.6 ± 3.2#ᶲ

0

8.3 ±
1.15*#

0

0

Amikacin Activity Results
50:50

1%:1%

1%:0.5%

Figure N: Zone of inhibition photographs for amikacin loaded chitosan/PEG paste over
72 hours (n = 3).
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Vancomycin Activity Results
50:50

1%:1%

1%:0.5%

Figure O: Zone of inhibition photographs for vancomycin loaded chitosan/PEG paste
over 72 hours (n = 3).
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APPENDIX G: IACUC ANIMAL USE PROTOCOL APPROVAL LETTER UofM
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APPENDIX H: IACUC ANIMAL USE PROTOCOL APPROVAL LETTER UAMS
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